-+ 0.00%
-+ 0.00%
-+ 0.00%

C4 THERAPEUTICS PRESENTS NEW BIOMARKER DATA FROM THE CEMSIDOMIDE PHASE 1 TRIAL WITH DEXAMETHASONE AND PHASE 1B TRIAL WITH ELRANATAMAB (ELREXFIO®) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA AT THE 23RD INTERNATIONAL MYELOMA SOCIETY (IMS) ANNUAL MEETING

Reuters·09/25/2026 11:01:06

Veuillez vous connecter pour afficher les détails des actualités